Bibliotecas PUC-SP - Busca Integrada

LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY

Yazar: E Crusoe, T Facon, P Moreau, I Spicka, K Suzuki, K Yong, J Mikhael, T Fukao, N Armstrong, T Martin
Yayımlandı Hematology, Transfusion and Cell Therapy (2023-10-01)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDO...

Yazar: H. Quach, X. Leleu, M.-V. Mateos, S. Z. Usmani, A. K. Nooka, A. Goldrick, R. Najdi, N. Shu, T. Facon
Yayımlandı HemaSphere (2022-06-01)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABE...

Yazar: A. Maiolino, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin
Yayımlandı Hematology, Transfusion and Cell Therapy (2020-11-01)

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-lab...

Yazar: M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin
Yayımlandı Hematology, Transfusion and Cell Therapy (2020-10-01)

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA

Yazar: L. Hasan Bou Issa, L. Fléchon, W. Laine, A. Ouelkdite, G. Escure, S. Gaggero, T. Ingegnere, R. Sklavenitis Pistofidis, I. M. Ghobrial, T. Facon, S. Mitra, J. Kluza, B. Quesnel, S. Manier
Yayımlandı HemaSphere (2022-06-01)

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER...

Yazar: H. Quach, A. Nooka, O. Samoylova, C.P. Venner, T. Facon, A. Spencer, S.Z. Usmani, K. Weisel, M. Mateos, K. Kim, S. Grosicki, K. Suzuki, S. Delimpasi, M. Obreja, A. Zahlten-Kumeli
Yayımlandı Hematology, Transfusion and Cell Therapy (2020-11-01)

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF T...

Yazar: T. Facon, S. K. Kumar, T. Plesner, P. Moreau, N. Bahlis, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. P. Venner, K. Weisel, J. R. Mace, N. Raje, M. Tiab, M. Macro, L. Frenzel, X. Leleu, H. Pei, F. Borgsten, S. Z. Usmani
Yayımlandı HemaSphere (2022-06-01)

C003 | MODELING LONG-TERM PROGRESSION-FREE SURVIVAL IN TRANSPLANT-ELIGIBLE AND TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, BORTEZOMIB, LENALIDO...

Yazar: F. Gay, P. Sonneveld, S. Zweegman, T. Facon, V. Hungria, N. J. Bahlis, P. Moreau, H. Einsele, M. Boccadoro, F. Borgsten, A. Lam, M. Nobrega, V. Kovacs, J. Wang, M. Rowe, A. Sitthi-Amorn, R. Carson, M.A. Dimopoulos, P. Rodríguez-Otero, S.Z. Usmani
Yayımlandı Haematologica (2025-09-01)

DP111 | POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY AND MINIMAL RESIDUAL DISEASE FOR EFFICACY ASSESSMENT IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: IMROZ...

Yazar: E. Zamagni, T. Facon, M.A. Dimopoulos, X. Leleu, M. Beksac, L. Pour, R. Hajek, Z. Liu, J. Minarik, P. Moreau, J. Romejko-Jarosinska, I. Spicka, T.G. Martin, L. Qiu, C. Sachpekidis, E. Kodas, H. Van De Velde, L. Zhao, R. Orlowski, H. Goldschmidt
Yayımlandı Haematologica (2025-09-01)

P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRM...

Yazar: A. Nooka, S. Lonial, S. Grosicki, M. Hus, K. Song, T. Facon, N. S. Callander, V. Ribrag, K. Uttervall, H. Quach, V. Vorobyev, C.-K. Min, S. Cheng, L. M. Smith, J. Yu, T. Collingwood, B. Holkova, B. E. Kremer, I. V. Gupta, P. G. Richardson, M. C. Minnema
Yayımlandı HemaSphere (2022-06-01)

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Yazar: N. W. C. J van de Donk, R Popat, C Hulin, S Jagannath, A Oriol, P. G Richardson, T Facon, K Weisel, J. T Larsen, M Minnema, A Abdallah, A. Z Badros, S Knop, E. A Stadtmauer, M Chen, T. V Nguyen, A Amin, T Peluso, S Lonial
Yayımlandı HemaSphere (2022-04-01)

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP...

Yazar: T. Facon, T. Plesner, S. Usmani, S. Kumar, N. Bahlis, C. Hulin, R. Orlowski, H. Nahi, P. Mollee, K. Ramasamy, M. Roussel, A. Jaccard, M. Delforge, L. Karlin, B. Arnulf, A. Chari, H. Pei, N. Gupta, S. Kaila, K. Matt, K. Gries, R. Carson, F. Borgsten, K. Weisel, A. Perrot
Yayımlandı HemaSphere (2023-05-01)

DP114 | ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA AND PLASMACYTOMAS: IMROZ SUBGROUP ANALYSIS

Yazar: E. Zamagni, T. Facon, M.A. Dimopoulos, X. Leleu, M. Beksac, L. Pour, R. Hajek, Z. Liu, J. Minarik, P. Moreau, J. Romejko-Jarosinska, I. Spicka, V. Vorobyev, T.G. Martin, L, Qiu, C. Sachpekidis, E. Kodas, Z. Klippel, U. Khan, H. Van De Velde, R. Z. Orlowski, H. Goldschmidt
Yayımlandı Haematologica (2025-09-01)

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA...

Yazar: K. Weisel, S. Kumar, P. Moreau, N. Bahlis, T. Facon, T. Plesner, R. Orlowski, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. Venner, N. Raje, M. Tiab1, M. Macro, L. Frenzel, X. Leleu, H. Pei, M Krevvata, R Carson, F. Borgsten, S. Usmani
Yayımlandı HemaSphere (2023-05-01)

Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogen...

Yazar: S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia
Yayımlandı Hematology Reports (2020-09-01)

S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN...

Yazar: C. Hasselbalch Riley, M. Hutchings, S.-S. Yoon, Y. Koh, S. Manier, T. Facon, S. J. Harrison, J. Er, F. Volzone, A. Pinto, C. Montes, E. M. Ocio, A. Alfonso-Pierola, P. Rodriguez Otero, F. Offner, A. Guidetti, P. Corradini, C. Titouan, C. Hulin, C. Touzeau, P. Moreau, R. Popat, S. Leong, R. Mazza, A.-M. E. Bröske, I. Dekhtiarenko, H.-J. Helms, S. Belli, T. Vardar, T. Fauti, J. Eckmann, T. Moore, M. Schneider, W. Jacob, M. Weisser, C. Carlo-Stella
Yayımlandı HemaSphere (2022-06-01)

S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULT...

Yazar: I. Dekhtiarenko, I. Lelios, J. Attig, N. Sleiman, D. Lazzaro, I. Clausen, N. Gräfe, H.-J. Helms, E. Schindler, S. Belli, T. Fauti, J. Eckmann, P. Umana, W. Jacob, M. Schneider, C. Hasselbalch Riley, M. Hutchings, S.-S. Yoon, Y Koh, S. Manier, T. Facon, S. J. Harrison, J. Er, F. Volzone, A. Pinto, C. Montes, E. M. Ocio, A. Alfonso-Pierola, P. Rodríguez Otero, F. Offner, A. Guidetti, P. Corradini, C. Titouan, C. Hulin, C. Touzeau, P. Moreau, R. Popat, S. Leong, R. Mazza, C. Carlo-Stella, A.-M. E. Bröske
Yayımlandı HemaSphere (2022-06-01)